Cargando…

Retinol and Retinol Binding Protein 4 Levels and Cardiometabolic Disease Risk

Despite mechanistic studies linking retinol and RBP4 (retinol binding protein 4) to the pathogenesis of cardiovascular diseases (CVD) and type 2 diabetes (T2D), epidemiological evidence is still conflicting. We investigated whether conflicting results of previous studies may be explained by differen...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiborn, Catarina, Weber, Daniela, Grune, Tilman, Biemann, Ronald, Jäger, Susanne, Neu, Natascha, Müller von Blumencron, Marie, Fritsche, Andreas, Weikert, Cornelia, Schulze, Matthias B., Wittenbecher, Clemens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9473720/
https://www.ncbi.nlm.nih.gov/pubmed/36017698
http://dx.doi.org/10.1161/CIRCRESAHA.122.321295
_version_ 1784789563556757504
author Schiborn, Catarina
Weber, Daniela
Grune, Tilman
Biemann, Ronald
Jäger, Susanne
Neu, Natascha
Müller von Blumencron, Marie
Fritsche, Andreas
Weikert, Cornelia
Schulze, Matthias B.
Wittenbecher, Clemens
author_facet Schiborn, Catarina
Weber, Daniela
Grune, Tilman
Biemann, Ronald
Jäger, Susanne
Neu, Natascha
Müller von Blumencron, Marie
Fritsche, Andreas
Weikert, Cornelia
Schulze, Matthias B.
Wittenbecher, Clemens
author_sort Schiborn, Catarina
collection PubMed
description Despite mechanistic studies linking retinol and RBP4 (retinol binding protein 4) to the pathogenesis of cardiovascular diseases (CVD) and type 2 diabetes (T2D), epidemiological evidence is still conflicting. We investigated whether conflicting results of previous studies may be explained by differences in the association of retinol and RBP4 with cardiometabolic risk across subgroups with distinct sex, hypertension state, liver, or kidney function. METHODS: We used case-cohorts nested in the EPIC (European Prospective Investigation Into Cancer and Nutrition)-Potsdam cohort (N=27 548) comprising a random sample of participants (n=2500) and all physician-verified cases of incident CVD (n=508, median follow-up time 8.2 years) and T2D (n=820, median follow-up time 6.3 years). We estimated nonlinear and linear multivariable-adjusted associations between the biomarkers and cardiometabolic diseases by restricted cubic splines and Cox regression, respectively, testing potential interactions with hypertension, liver, and kidney function. Additionally, we performed 2-sample Mendelian Randomization analyses in publicly available data. RESULTS: The association of retinol with cardiometabolic risk was modified by hypertension state (P interaction CVD<0.001; P interaction T2D<0.001). Retinol was associated with lower cardiometabolic risk in participants with treated hypertension (hazard ratio(per SD) [95% CI]: CVD, 0.71 [0.56–0.90]; T2D, 0.81 [0.70–0.94]) but with higher cardiometabolic risk in normotensive participants (CVD, 1.32 [1.06–1.64]; T2D, 1.15 [0.98–1.36]). Our analyses also indicated a significant interaction between RBP4 and hypertension on CVD risk (P interaction=0.04). Regarding T2D risk, we observed a u-shaped association with RBP4 in women (P nonlinearity=0.01, P effect=0.02) and no statistically significant association in men. The biomarkers’ interactions with liver or kidney function were not statistically significant. Hypertension state-specific associations for retinol concentrations with cardiovascular mortality risk were replicated in National Health and Nutrition Examination Survey III. CONCLUSIONS: Our findings suggest a hypertension-dependent relationship between plasma retinol and cardiometabolic risk and complex interactions of RBP4 with sex and hypertension on cardiometabolic risk.
format Online
Article
Text
id pubmed-9473720
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94737202022-09-21 Retinol and Retinol Binding Protein 4 Levels and Cardiometabolic Disease Risk Schiborn, Catarina Weber, Daniela Grune, Tilman Biemann, Ronald Jäger, Susanne Neu, Natascha Müller von Blumencron, Marie Fritsche, Andreas Weikert, Cornelia Schulze, Matthias B. Wittenbecher, Clemens Circ Res Original Research Despite mechanistic studies linking retinol and RBP4 (retinol binding protein 4) to the pathogenesis of cardiovascular diseases (CVD) and type 2 diabetes (T2D), epidemiological evidence is still conflicting. We investigated whether conflicting results of previous studies may be explained by differences in the association of retinol and RBP4 with cardiometabolic risk across subgroups with distinct sex, hypertension state, liver, or kidney function. METHODS: We used case-cohorts nested in the EPIC (European Prospective Investigation Into Cancer and Nutrition)-Potsdam cohort (N=27 548) comprising a random sample of participants (n=2500) and all physician-verified cases of incident CVD (n=508, median follow-up time 8.2 years) and T2D (n=820, median follow-up time 6.3 years). We estimated nonlinear and linear multivariable-adjusted associations between the biomarkers and cardiometabolic diseases by restricted cubic splines and Cox regression, respectively, testing potential interactions with hypertension, liver, and kidney function. Additionally, we performed 2-sample Mendelian Randomization analyses in publicly available data. RESULTS: The association of retinol with cardiometabolic risk was modified by hypertension state (P interaction CVD<0.001; P interaction T2D<0.001). Retinol was associated with lower cardiometabolic risk in participants with treated hypertension (hazard ratio(per SD) [95% CI]: CVD, 0.71 [0.56–0.90]; T2D, 0.81 [0.70–0.94]) but with higher cardiometabolic risk in normotensive participants (CVD, 1.32 [1.06–1.64]; T2D, 1.15 [0.98–1.36]). Our analyses also indicated a significant interaction between RBP4 and hypertension on CVD risk (P interaction=0.04). Regarding T2D risk, we observed a u-shaped association with RBP4 in women (P nonlinearity=0.01, P effect=0.02) and no statistically significant association in men. The biomarkers’ interactions with liver or kidney function were not statistically significant. Hypertension state-specific associations for retinol concentrations with cardiovascular mortality risk were replicated in National Health and Nutrition Examination Survey III. CONCLUSIONS: Our findings suggest a hypertension-dependent relationship between plasma retinol and cardiometabolic risk and complex interactions of RBP4 with sex and hypertension on cardiometabolic risk. Lippincott Williams & Wilkins 2022-08-26 2022-09-16 /pmc/articles/PMC9473720/ /pubmed/36017698 http://dx.doi.org/10.1161/CIRCRESAHA.122.321295 Text en © 2022 The Authors. https://creativecommons.org/licenses/by/4.0/Circulation Research is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.
spellingShingle Original Research
Schiborn, Catarina
Weber, Daniela
Grune, Tilman
Biemann, Ronald
Jäger, Susanne
Neu, Natascha
Müller von Blumencron, Marie
Fritsche, Andreas
Weikert, Cornelia
Schulze, Matthias B.
Wittenbecher, Clemens
Retinol and Retinol Binding Protein 4 Levels and Cardiometabolic Disease Risk
title Retinol and Retinol Binding Protein 4 Levels and Cardiometabolic Disease Risk
title_full Retinol and Retinol Binding Protein 4 Levels and Cardiometabolic Disease Risk
title_fullStr Retinol and Retinol Binding Protein 4 Levels and Cardiometabolic Disease Risk
title_full_unstemmed Retinol and Retinol Binding Protein 4 Levels and Cardiometabolic Disease Risk
title_short Retinol and Retinol Binding Protein 4 Levels and Cardiometabolic Disease Risk
title_sort retinol and retinol binding protein 4 levels and cardiometabolic disease risk
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9473720/
https://www.ncbi.nlm.nih.gov/pubmed/36017698
http://dx.doi.org/10.1161/CIRCRESAHA.122.321295
work_keys_str_mv AT schiborncatarina retinolandretinolbindingprotein4levelsandcardiometabolicdiseaserisk
AT weberdaniela retinolandretinolbindingprotein4levelsandcardiometabolicdiseaserisk
AT grunetilman retinolandretinolbindingprotein4levelsandcardiometabolicdiseaserisk
AT biemannronald retinolandretinolbindingprotein4levelsandcardiometabolicdiseaserisk
AT jagersusanne retinolandretinolbindingprotein4levelsandcardiometabolicdiseaserisk
AT neunatascha retinolandretinolbindingprotein4levelsandcardiometabolicdiseaserisk
AT mullervonblumencronmarie retinolandretinolbindingprotein4levelsandcardiometabolicdiseaserisk
AT fritscheandreas retinolandretinolbindingprotein4levelsandcardiometabolicdiseaserisk
AT weikertcornelia retinolandretinolbindingprotein4levelsandcardiometabolicdiseaserisk
AT schulzematthiasb retinolandretinolbindingprotein4levelsandcardiometabolicdiseaserisk
AT wittenbecherclemens retinolandretinolbindingprotein4levelsandcardiometabolicdiseaserisk